<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Campbell | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/brianhouse60/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/brianhouse60/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Campbell.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">8003a3cc00dbe2fa9e6e02e48ded1862</guid>
				<title>Campbell posted an update: AR-15512 (formerly known as AVX-012 and WS-12) is a TRPM8 [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/42699/</link>
				<pubDate>Sun, 09 Feb 2025 10:48:36 -0800</pubDate>

									<content:encoded><![CDATA[<p>AR-15512 (formerly known as AVX-012 and WS-12) is a TRPM8 receptor agonist currently in phase 2b clinical trials for the treatment of dry eye. This bioactive compound with menthol-like cooling activity has three stereogenic centers, and its final structure and absolute configuration, (1R,2S,5R), have been previously solved by cryo-electron&hellip;<span class="activity-read-more" id="activity-read-more-42699"><a href="http://www.nationalboardinstitute.com/activity/p/42699/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">1fa5171207fb1c415918ac56926c3399</guid>
				<title>Campbell posted an update: Development of the technology and app/software is required [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41060/</link>
				<pubDate>Fri, 07 Feb 2025 10:57:00 -0800</pubDate>

									<content:encoded><![CDATA[<p>Development of the technology and app/software is required so that more data can be processed at higher speed. Use of VR technology with a live communication tool could be an alternative teaching method. Its overall advantages are a closer look at the slides/monitor and concurrent observation of the multiple assets in various directions by&hellip;<span class="activity-read-more" id="activity-read-more-41060"><a href="http://www.nationalboardinstitute.com/activity/p/41060/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">eab33dd615d5d127983f6cbb1ae64132</guid>
				<title>Campbell posted an update: 80 95%CI [71, 91]) and incident mobility disability (HR [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/38376/</link>
				<pubDate>Tue, 04 Feb 2025 11:16:27 -0800</pubDate>

									<content:encoded><![CDATA[<p>80 95%CI [71, 91]) and incident mobility disability (HR 0.81, 95%CI [0.70, 0.93]). Further analyses suggest that grip strength and gait speed rather than muscle mass drive the associations with all four adverse health outcomes. Similar findings were observed when controlling for additional measures used to assess physical frailty including BMI,&hellip;<span class="activity-read-more" id="activity-read-more-38376"><a href="http://www.nationalboardinstitute.com/activity/p/38376/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">1892c6894aef271d7c0099f3303c66c5</guid>
				<title>Campbell posted an update: comparison to influenza patients. These results reinforce [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/36471/</link>
				<pubDate>Sun, 02 Feb 2025 10:36:44 -0800</pubDate>

									<content:encoded><![CDATA[<p>comparison to influenza patients. These results reinforce current clinical guidelines on antibiotic management in COVID-19, which only advise utilization of antibiotics when a bacterial co-infection is suspected.</p>
<p>We report a very low occurrence of community-acquired bacteraemia amongst COVID-19 patients in comparison to influenza patients.&hellip;<span class="activity-read-more" id="activity-read-more-36471"><a href="http://www.nationalboardinstitute.com/activity/p/36471/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">872589f6f3316fd30f8d11d5af8745cd</guid>
				<title>Campbell posted an update: Dermatology being a visual branch, there is a need to add a [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/32078/</link>
				<pubDate>Tue, 28 Jan 2025 17:52:37 -0800</pubDate>

									<content:encoded><![CDATA[<p>Dermatology being a visual branch, there is a need to add a visual element in learning and assessment of dermatology. This study compares the utility of image-based assessment (IBA) as a new tool compared to routinely used semi-structured viva (SSV) in dermatology formative assessment at undergraduate level.</p>
<p> Comparison was made between&hellip;<span class="activity-read-more" id="activity-read-more-32078"><a href="http://www.nationalboardinstitute.com/activity/p/32078/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">01e7ae5e5b03cde8f14dc59277dcda94</guid>
				<title>Campbell became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/32042/</link>
				<pubDate>Tue, 28 Jan 2025 17:49:29 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>